JPMorgan lifts Teva price target to $50 after Weltruza approval
JPMorgan raised its price target for Teva Pharmaceutical Industries to $50 from $40 following FDA approval of Weltruza, the company’s long‑acting olanzapine injectable. The bank projects Weltruza will generate $125 million in sales in 2027 and $350 million in 2028. JPMorgan kept an Overweight rating in one note and an Underweight rating in another. The target increase reflects the bank’s view of a new growth opportunity for Teva’s injectable franchise.
Why it matters
The higher target suggests upside potential for Teva’s share price, as investors weigh the projected sales of Weltruza. JPMorgan’s forecasts provide a concrete revenue outlook for the product’s early years.
Key facts
- 1JPMorgan raised its price target on Teva to $50 from $40. tipranks.com
- 2The price target increase follows FDA approval of Weltruza, a long‑acting olanzapine injectable. investing.com
- 3JPMorgan expects Weltruza to generate $125 million in sales in 2027. investing.com
- 4JPMorgan expects Weltruza sales to ramp to $350 million in 2028. investing.com
- 5JPMorgan maintained an Overweight rating in its tipranks note. tipranks.com
- 6JPMorgan maintained an Underweight rating in its investing.com note. investing.com
Open questions
- JPMorgan’s rating differs between sources (Overweight vs Underweight).
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.